Norwegian Sequencing Centre - Phase II
About the project
The Norwegian Sequencing Centre (NSC) has been operating as a national core facility for high-throughput DNA sequencing (HTS) since 2009. The two partners behind NSC - the Centre for Ecological and Evolutionary Synthesis (CEES) and the Department of Medical Genetics (DMG) - represent leading scientific environments within biology and medical genetics, respectively, and are both heavily involved in numerous projects using HTS. We have users from all over Norway as well as internationally - from both public and private sector. We have experienced a huge increase in projects and users at NSC, and at present our instrumentation, particularly the Illumina machines, are run to the limits of their capacity.
In Phase II, we will take NSC to the next level, increasing the capacity and extending our services to the level needed to provide "state-of-the-art" services at an internationally competitive level in the years to come. Several large and high profiled sequencing projects, in both biology and medicine, are in the pipeline at NSC. For example, CEES has recently been awarded a significant grant - "the AquaGenome Project" - from the RCN BIOTEK 2021 programme, where we aim at sequencing one thousand genomes of both cod and salmon. To handle such large-scale projects nationally, it is essential to increase our sequencing capacity by obtaining more equipment, personnel and strengthening our IT infrastructure. In addition to three new Illumina machines, we will implement new, improved sequencing technology.
Another important aspect of the project is to extend our services in bioinformatic analysis, frequently a bottleneck for many of our users.
Futhermore, in Phase II we will increase our international collaboration and will take the initiative to form a network of leading Scandinavian sequencing centres in order to increase transfer of technology and know-how, as well as enabling collaborations on large sequencing projects to the benefit of our users.
This project is financed by the Research Council of Norway.
The Department of Medical Genetics of the University of Oslo
01.01.2014 - 21.12.2020